Department of Dermatology, Venerology and Allergology, University of Essen-Duisburg, Essen, Germany.
J Eur Acad Dermatol Venereol. 2012 Feb;26(2):200-6. doi: 10.1111/j.1468-3083.2011.04036.x. Epub 2011 Mar 17.
Complete lymph node dissection (CLND) in melanoma patients with a positive sentinel lymph node (SLN) is currently being debated, as it is a cost-intensive surgical intervention with potentially high morbidity.
This clinical study seeks to clarify the effectiveness, reliability and cost-effectiveness of CLND performed under tumescent local anaesthesia (TLA) compared with procedures under general anaesthesia (GA).
We retrospectively analysed the data from 60 patients with primary malignant melanoma American Joint Committee on Cancer stage III who underwent CLND.
Altogether 26 (43.3%) patients underwent CLND under TLA and 34 (56.7%) patients underwent CLND under GA. Fifteen of 43 (34.9%) patients had a complication, such as development of seromas and/or wound infections. The rate of complications was 25.0% (3/12) in the axilla subgroup and 28.6% (4/14) in the groin subgroup of the TLA group. In the GA group, the complication rate was 31.3% (5/16) in the axilla subgroup and 44.4% (8/18) in the groin subgroup. The costs for CLND were significantly less for the CLND in a procedure room performed under TLA (mean €67.26) compared with CLND in an operating room under GA (mean €676.20, P < 0.0001).
In conclusion, this study confirms that TLA is an excellent, safe, effective and cost-efficient alternative to GA for CLND in melanoma patients.
目前对于前哨淋巴结阳性的黑色素瘤患者是否行完全淋巴结清扫术(CLND)仍存在争议,因为这是一种具有潜在高发病率且耗费成本高的手术干预措施。
本临床研究旨在明确在肿胀局部麻醉(TLA)下进行 CLND 的有效性、可靠性和成本效益,与全身麻醉(GA)下的手术相比。
我们回顾性分析了 60 例接受 CLND 的原发性恶性黑色素瘤美国癌症联合委员会(AJCC)分期 III 期患者的数据。
共有 26 例(43.3%)患者在 TLA 下接受 CLND,34 例(56.7%)患者在 GA 下接受 CLND。43 例患者中有 15 例(34.9%)出现并发症,如血清肿和/或伤口感染。TLA 组的腋窝亚组并发症发生率为 25.0%(3/12),腹股沟亚组为 28.6%(4/14)。GA 组的腋窝亚组并发症发生率为 31.3%(5/16),腹股沟亚组为 44.4%(8/18)。TLA 下在诊室进行的 CLND 的费用明显低于 GA 下在手术室进行的 CLND(TLA 下平均€67.26,GA 下平均€676.20,P<0.0001)。
综上所述,本研究证实 TLA 是黑色素瘤患者 CLND 的一种极好、安全、有效且具有成本效益的 GA 替代方法。